Search research articles
Contact Us
Filters
Showing results (101-110 of 274) with videos related to
Page
of 28
Sort By:
Blood
|
October 30, 2016
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
Ya-Wei Qiang, Shiqiao Ye, Yu Chen, et al.
Oncotarget
|
September 2, 2015
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
Frits van Rhee, Corey Casper, Peter M Voorhees, et al.
The Patient
|
March 5, 2015
Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab
Frits van Rhee, Margaret Rothman, Kai Fai Ho, et al.
International Journal of Molecular Sciences
|
December 23, 2022
Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate Model
Tarun K Garg, Sarita Garg, Isabelle R Miousse, et al.
Blood
|
January 27, 2005
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Frits van Rhee, Susann M Szmania, Fenghuang Zhan, et al.
American Journal of Hematology
|
March 5, 2013
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Rakesh Bam, Wen Ling, Sharmin Khan, et al.
Radiation Research
|
December 7, 2023
Modulation of Hematopoietic Injury by a Promising Radioprotector, Gamma-Tocotrienol, in Rhesus Macaques Exposed to Partial-Body Radiation
Tarun K Garg, Sarita Garg, Isabelle R Miousse, et al.
British Journal of Haematology
|
May 4, 2022
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry
David C Fajgenbaum, Sheila K Pierson, Karan Kanhai, et al.
Blood
|
December 3, 2005
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
Bart Barlogie, Guido Tricot, Erik Rasmussen, et al.
American Journal of Hematology
|
May 29, 2021
Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma
Meera Mohan, Aniko Szabo, Naveen Yarlagadda, et al.
Page
of 28
Search research articles
Search
Showing results (101-110 of 274) with videos related to
Sort By:
Page
of 28
Blood
|
October 30, 2016
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
Ya-Wei Qiang, Shiqiao Ye, Yu Chen, et al.
Oncotarget
|
September 2, 2015
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
Frits van Rhee, Corey Casper, Peter M Voorhees, et al.
The Patient
|
March 5, 2015
Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab
Frits van Rhee, Margaret Rothman, Kai Fai Ho, et al.
International Journal of Molecular Sciences
|
December 23, 2022
Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate Model
Tarun K Garg, Sarita Garg, Isabelle R Miousse, et al.
Blood
|
January 27, 2005
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Frits van Rhee, Susann M Szmania, Fenghuang Zhan, et al.
American Journal of Hematology
|
March 5, 2013
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Rakesh Bam, Wen Ling, Sharmin Khan, et al.
Radiation Research
|
December 7, 2023
Modulation of Hematopoietic Injury by a Promising Radioprotector, Gamma-Tocotrienol, in Rhesus Macaques Exposed to Partial-Body Radiation
Tarun K Garg, Sarita Garg, Isabelle R Miousse, et al.
British Journal of Haematology
|
May 4, 2022
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry
David C Fajgenbaum, Sheila K Pierson, Karan Kanhai, et al.
Blood
|
December 3, 2005
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
Bart Barlogie, Guido Tricot, Erik Rasmussen, et al.
American Journal of Hematology
|
May 29, 2021
Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma
Meera Mohan, Aniko Szabo, Naveen Yarlagadda, et al.
Page
of 28